Summit Corporation plc Stock London S.E.
Equities
GB00B02T3K57
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- GBX | - |
05-07 | Citigroup Starts Summit Therapeutics With Buy Rating, $7 Price Target | MT |
05-01 | Transcript : Summit Therapeutics Inc., Q1 2024 Earnings Call, May 01, 2024 |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 2.51B 3.19B 4.35B |
---|---|---|---|---|---|
Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 11.86% |
Latest transcript on Summit Corporation plc
Managers | Title | Age | Since |
---|---|---|---|
Mahkam Zanganeh
CEO | Chief Executive Officer | 52 | 20-11-10 |
Robert Duggan
CEO | Chief Executive Officer | 79 | 19-11-30 |
Director of Finance/CFO | 46 | 19-11-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Duggan
CEO | Chief Executive Officer | 79 | 19-11-30 |
Robert Booth
BRD | Director/Board Member | 70 | 22-09-27 |
Director of Finance/CFO | 46 | 19-11-30 |
1st Jan change | Capi. | |
---|---|---|
+8.63% | 115B | |
+13.17% | 107B | |
-12.76% | 22.31B | |
-3.99% | 21.6B | |
-7.19% | 18.23B | |
-39.93% | 17.62B | |
+6.67% | 14.26B | |
+33.90% | 12.37B | |
-28.60% | 8.28B |